Sourcing clinical trial supplies with maximum batch diversity and origin conditions
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Sourcing clinical trial supplies with maximum batch diversity and origin conditions

12 Apr 2021

Sponsored by Aposave Sponsored by Visit Company
Sourcing clinical trial supplies with maximum batch diversity and origin conditions

Having the support of a strong network is critical for companies that provide access and supply medicine for clinical trials and managed access programs. Aposave, an international healthcare and pharma services provider, spoke to Pharmaceutical Technology about a case study where a client needed Aposave’s network and expertise to source EU-based clinical trial supplies.

Aposave provides access to specialty medicines for clinical researchers working in pharmaceutical, biotechnology and biosimilar companies. One of the company’s clients is a large multinational pharmaceutical company that harnesses new technologies to develop medications that address unmet medical needs.

The client’s expansive clinical pipeline covers indications where there are already standards of care and multiple treatment options available, therefore its clinical development strategy involves reference product evaluation. This requires multiple batches of medicines in varying quantities and from several countries.

Challenges for the company arise because closed market sourcing for small quantities of analytical medicines is often not possible. Suppliers of clinical materials rarely have access to small trial quantities. When they do, this will usually be restricted to material the manufacturer has produced for trial purposes, amounting to a single batch from the country of origin.

From the perspectives of pricing, availability and quality standards, Europe is the best market for sourcing these reference products due to the practice of price variation in the EU which allows for the free movement of the same goods from multiple origins. However, medicines that are released for those domestic commercial markets are generally kept within the normalised supply chain and not exported to other territories or sales channels.

Aposave’s solution

Aposave’s parent organisation, Abacus Medicine, is one of Europe’s largest distributors of specialty medicines. A holder of more than 6,200 marketing authorisations and part of a global network, Abacus Medicine has the majority of specialty medicines either in-stock or inbound to one of its many European depots. In 2020, the company distributed more than 14 million units of medicine.

Harnessing the European procurement resources of its parent company and its own clinical supplies expertise, Aposave’s services represented the ideal solution to the client’s reference product sourcing challenges. Aposave now delivers a unique service to the client, allowing for the collection of maximum batches with a range of expiry conditions from across the EU.

Free Case Study

Drastically reducing the risk of unplanned comparator clinical trial costs

Comparator trials that weigh the benefits of bringing new drugs to market with the efficacy of existing therapies can be costly and unwieldy – particularly as the new therapy is usually sourced at phases II and III, leaving unused, expensive inventory for sponsors to deal with.

With patient recruitment problems also being a well-documented issue associated with clinical trials, this may also lead to unplanned build-up of expiry date issues with trial comparator inventory.

So, what’s the best solution? In this whitepaper, clinical trial services company Aposave explores the challenges and solutions faced by clients engaged in these trials. To learn more about how you can ethically and cost-effectively deal with these issues, download the free whitepaper below.

By clicking the “Submit” button above, you accept the Terms & Conditions and acknowledge that your data will be used as described in the Aposave Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.